Name: 글로벌 시장 동향
SKU: PH7217
Availability: InStock

보고서 요약(국문)

개요
전 세계 종양 내 암 치료 시장은 2022년 YY백만 달러에 도달했으며, 2023년부터 2030년까지 연평균 성장률(CAGR) YY%로 성장하여 2030년에는 YY백만 달러에 이를 것으로 예상됩니다.
종양 내 면역 요법은 종양 자체를 백신처럼 이용하여 종양을 표적으로 하는 유망한 치료 접근법입니다. 이는 종양에 직접 주사하여 종양의 국소 면역 반응을 직접적으로 표적하는 효과적인 방법입니다.
또한, 종양과 해부학적으로 인접한 부위에 있는 종양을 공격하여 종양에 직접 흡수되도록 할 수도 있습니다. 종양 내 치료법에는 사이토카인, 병원체 관련 분자 패턴(PAMP), 용해성 바이러스, 암 유전자 치료, 단클론 항체, 소분자 약물 등 다양한 유형이 있습니다.

시장 동향: 성장 동력 및 제약 요인
시장 개발 증가
전 세계 종양 내 암 치료제 시장의 개발이 증가함에 따라 예측 기간 동안 글로벌 시장 성장이 촉진될 것으로 예상됩니다. 예를 들어, 2023년 1월 영국에 본사를 둔 과학 중심 바이오제약 기업인 아스트라제네카는 네오진 테라퓨틱스(Neogene Therapeutics Inc.)를 1억 2천만 달러에 인수했으며, 이 인수를 통해 아스트라제네카는 암 치료 분야에서 새로운 가능성을 열 것으로 기대됩니다.
또한, 2022년 리제네론은 임상 단계 바이오제약 기업인 체크메이트 파마슈티컬(Checkmate Pharmaceutical)을 인수했으며, 이 회사의 면역 활성화제는 다양한 종양 유형에 적용될 가능성이 있습니다. 이 밖에도, 인식 제고, 임상 사례 증가, 연구 활동 활성화 등 여러 요인이 예측 기간 동안 글로벌 시장 성장에 기여할 것으로 예상됩니다.

종양 내 항암 치료와 관련된 부작용
그러나 암 치료로 인해 발생하는 흔하고 드물지만 심각한 부작용이 많아 예측 기간 동안 세계 시장 성장을 저해할 것으로 예상됩니다. 또한, 승인된 치료법의 부족, 높은 비용, 전문가 부족 등이 세계 시장 성장을 저해하는 추가적인 요인입니다.
세분화 분석
세계 종양 내 항암 치료 시장은 기술, 암 유형, 최종 사용자 및 지역별로 세분화됩니다.
폐암이 시장을 주도할 것으로 예상됨
폐암에 대한 신제품 승인 증가로 인해 해당 부문의 성장이 촉진되고 있으며, 예측 기간 동안 세계 시장을 주도할 것으로 예상됩니다. 예를 들어, 2021년 10월 미국 FDA는 2기 및 3기 비소세포폐암(NSCLC) 치료제로 테센트릭(아테졸리주맙)을 승인했습니다. 또한, 2022년 4월 미국 FDA는 성인 비소세포폐암(NSCLC) 환자 치료를 위해 옵디보(니볼루맙)를 승인했습니다. 더 나아가, 폐암 발병 사례의 증가와 연구 활동의 확대는 예측 기간 동안 세계 시장에서 해당 부문의 성장을 견인할 것으로 예상됩니다.

지역 분석
북미, 세계 시장 주도 예상
북미는 정부 투자 증가, 암 발병 사례 증가, 제품 승인 증가 등의 요인으로 인해 예측 기간 동안 세계 시장을 주도할 것으로 예상됩니다. 예를 들어, 2023년 미국 정부는 국립암연구소(NCI)의 암 연구를 위해 78억 달러의 예산을 편성했습니다.
정부와 민간 기관의 암 치료 연구 개발 확대를 위한 투자는 북미 종양내 항암 치료 시장의 성장을 견인하고 있습니다.

미국 암 협회에 따르면 2022년 미국에서 약 190만 건의 암 진단 사례가 발생했습니다. 또한, 글랜드 파마(Gland Pharma)는 2022년 미국에서 주사제 형태의 항암제 보르테조밉(Bortezomib)을 출시했습니다. 이 지역의 다양한 생명공학 및 의료기기 기업들은 연구 개발 투자 증가와 기술 보급 확대로 인해 예측 기간 동안에도 선두 자리를 유지할 것으로 예상됩니다.

COVID-19 영향 분석
암 환자는 암 또는 암 치료로 인해 면역 체계가 약화되어 COVID-19에 감염될 경우 중증 질환으로 발전할 위험이 높습니다. 과거에 암 치료를 받은 사람(특히 오래전에 치료를 받은 사람)은 정상적인 면역 기능을 유지할 가능성이 더 높습니다. 따라서 이는 예측 기간 동안 치료 수요에 영향을 미칠 수 있습니다.

시장 세분화
기술별
• 단클론 항체
• 백신
• 면역관문 억제제
• 세포 치료제
• 면역체계 조절제
• 입양 세포 치료
• 사이토카인
암 유형별
• 폐암
• 유방암
• 흑색종
• 전립선암
• 두경부암
• 기타
최종 사용자별
• 병원
• 암 연구 센터
• 클리닉
지역별
• 북미
o 미국
o 캐나다
o 멕시코
• 유럽
o 독일
o 영국
o 프랑스
o 이탈리아
o 스페인
o 기타 유럽
• 남미
o 브라질
o 아르헨티나
o 기타 남미
• 아시아 태평양
o 중국
o 인도
o 일본
o 호주
o 기타 아시아 태평양
• 중동 및 아프리카
주요 개발
• 2022년 7월, 머크는 오리온과 2억 9천만 달러 규모의 전립선암 신약 개발 계약을 체결했습니다.

• 2022년 7월, 필로젠(Philogen)은 국소 진행성 흑색종 치료를 위한 최신 종양내 투여 약물인 니들레지(Nidlegy)의 임상 3상 시험에 214명의 환자를 등록했다고 발표했습니다.
• 2022년 10월, 머크(Merck)는 모더마(Moderma)와 협력하여 흑색종 환자를 위한 맞춤형 종양내 항암 치료법을 개발 및 상용화하기로 했습니다.
경쟁 환경
이 시장의 주요 글로벌 업체로는 호프만-라로슈(Hoffmann-La Roche), 화이자(Pfizer), 브리스톨-마이어스 스큅(Bristol-Myers Squibb), 베링거 인겔하임(Boehringer Ingelheim GmbH), 사노피(Sanofi), 다이이치 산쿄(Daiichi Sankyo), 아스트라제네카(AstraZeneca), 이뮤노코어(Immunocore, Ltd), 머크(Merck and Co. Inc.), 바이오젠(Biogen Inc.) 등이 있습니다.

보고서 구매 이유

• 기술, 암 유형, 최종 사용자 및 지역별 글로벌 종양내 항암 치료법 시장 세분화를 시각화하고 주요 상업 자산 및 업체를 파악하기 위해.

• 트렌드 및 공동 개발 분석을 통해 상업적 기회를 식별하기 위해.

• 모든 세그먼트를 포함한 종양내 항암 치료 시장 수준의 다양한 데이터가 담긴 엑셀 데이터 시트.

• 심층적인 질적 인터뷰와 연구를 바탕으로 한 종합적인 분석이 담긴 PDF 보고서.

• 주요 업체들의 핵심 제품을 모두 포함하는 제품 맵핑 엑셀 파일 제공.
글로벌 종양내 항암 치료 시장 보고서는 약 61개의 표, 59개의 그림, 194페이지 분량입니다.
주요 독자층 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자은행
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
Global Intratumoral Cancer Therapies market reached US$ YY million in 2022 and is expected to reach US$ YY million by 2030, growing at a CAGR of YY% during the forecast period 2023-2030.
Intratumoral immunotherapy is a probable therapeutic approach that targets the tumor using it as a vaccine against itself. It is an advantageous method that encloses direct injection into the tumors thereby targeting the regional tumor immunity hindrances directly.
It can even be leveraged to attack any tumor that fibs in proximate anatomical closeness to a tumor with the intent of immediate uptake by tumors. There are distinct types of intratumoral therapies including cytokines, pathogen-associated molecular patterns (PAMPs), oncolytic viruses, cancer gene therapy, monoclonal antibodies, and small molecules.
Market Dynamics: Drivers & Restraints
Increasing Market Developments
The increasing market developments in the global Intratumoral Cancer Therapies market are expected to boost the global market growth during the forecast period. For instance, in January 2023, AstraZeneca, a UK-based, science-driven biopharmaceutical corporation completed the acquisition of Neogene Therapeutics Inc., for $120 million and this acquisition is expected to unlock further routes for AstraZeneca for the treatment of cancer.
Moreover, in 2022, Regeneron completed the acquisition of Checkmate Pharmaceutical, a clinical-stage biopharmaceutical corporation, and its investigational immune activator for probable usage in multiple tumor types. Furthermore, growing awareness, cases and research activites among other factors are also expected to contribute to the global market growth during the forecast period.
Side Effects Associated with these Intratumoral Cancer Therapies
However, the large number of common and uncommon severe side effects cuased by cancer therapy are expected to hamper the global market growth during the forecast period. Furthermore, the lack of approved treatments available, high cost and deficient number of professionals are among the additional factors hampering the global market growth.
Segment Analysis
The global intratumoral cancer therapies market is segmented based on technology, cancer type, end user and region.
Lung Cancer Type is Expected to Dominate Market
Owing to the increase in new product approvals for lung cancer boosting the segment growth, dominating the global market in the forecast period. For instance, in October 2021, the U.S. FDA authorized Tecentriq (atezolizumab) to treat stage II and stage III Non-small cell lung cancer (NSCLC). Moreover, in April 2022, the U.S. FDA authorized Opdivo (nivolumab) for the treatment of NSCLC in adult patients. Furthermore, the growing cases of Lung cancer along with the increasing research activities are also expected to contribute to the dominance of the segment on the global market in the forecast period.
Geographical Analysis
North America is Expected to Dominate the Global Market
North America is expected to dominate the global market during the forecast period due to increasing government investments, growing cancer cases, and increasing product authorizations among others. For instance, in 2023, the US government announced a budget of USD 7.8 billion to the National Cancer Institute (NCI) for cancer research.
The government and private organizations' investment to expand the research and development of cancer therapies in the region is driving the growth of the North America Intratumoral Cancer Therapy Market.
According to the American Cancer Society, around 1.9 million cases of cancer were diagnosed in the US in 2022. Additionally, Gland Pharma has launched the cancer treatment medicine Bortezomib for Injection in the United States in 2022. Furthermore, the presence of various biotechnology and medical device firms in this region is likely to maintain their lead during the forecast period due to increased spending on research and development initiatives and widespread use of technology in the region.
COVID-19 Impact Analysis
Since some individuals with cancer are at raised threat of severe illness if they get COVID-19, owing to their immune systems have been strained by the cancer and/or its therapies. Individuals who were treated for cancer in the history (particularly if it was years ago) are better potential to have normal immune function. Thus, impacting the therapy demand during the forecast period.
Market Segmentation
By Technology
• Monoclonal Antibodies
• Vaccines
• Checkpoint Inhibitors
• Cell Therapies
• Immunes System Modulator
• Adoptive Cell Transfer
• Cytokines
By Cancer Type
• Lung Cancer
• Breast Cancer
• Malenoma
• Prostate Cancer
• Head and Neck Cancer
• Other
By End User
• Hospitals
• Cancer Research Centres
• Clinics
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Key Developments
• In July 2022, Merck formed a USD290 million agreement with Orion to design a novel prostate cancer medicine.
• In July 2022, Philogen reported the enrolment of 214 patients for clinical trial 3 of its latest Intratumoral drug Nidlegy for the treatment of locally advanced melanoma cancer.
• In October 2022, Merck collaborated with Moderma to develop and commercialize personalized intratumoral cancer therapy for melanoma cancer.
Competitive Landscape
The major global players in the market include Hoffmann-La Roche, Pfizer, Bristol-Myers Squibb, Boehringer Ingelheim GmbH, Sanofi, Daiichi Sankyo, AstraZeneca, Immunocore, Ltd, Merck and Co. Inc. and Biogen Inc. among others.
Why Purchase the Report?
• To visualize the global intratumoral cancer therapies market segmentation based on technology, cancer type, end user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of intratumoral cancer therapies market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global intratumoral cancer therapies market report would provide approximately 61 tables, 59 figures and 194 pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Technology
3.2. Snippet by Cancer Type
3.3. Snippet by End User
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing Market Developments
4.1.1.2. YY
4.1.2. Restraints
4.1.2.1. Side Effects
4.1.2.2. YY
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Reimbursement Analysis
5.6. Patent Analysis
5.7. Pipeline Analysis
5.8. Epidemiology
5.9. SWOT Analysis
5.10. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Technology
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
7.1.2. Market Attractiveness Index, By Technology
7.2. Monoclonal Antibodies*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Vaccines
7.4. Checkpoint Inhibitors
7.5. Cell Therapies
7.6. Immunes System Modulator
7.7. Adoptive Cell Transfer
7.8. Cytokines
8. By Cancer Type
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
8.1.2. Market Attractiveness Index, By Cancer Type
8.2. Lung Cancer*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Breast Cancer
8.4. Malenoma
8.5. Prostate Cancer
8.6. Head and Neck Cancer
8.7. Other Applications
9. By End User
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9.1.2. Market Attractiveness Index, By End User
9.2. Hospital*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Cancer Research Centres
9.4. Clinics
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. UK
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Hoffmann-La Roche*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. Pfizer
12.3. Bristol-Myers Squibb, Inc.
12.4. Boehringer Ingelheim GmbH
12.5. Sanofi
12.6. Daiichi Sankyo
12.7. AstraZeneca, Inc.
12.8. Immunocore, Ltd
12.9. Biogen Inc.
12.10. Merck and Co. Inc.
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us

언급된 주요 기업들

Hoffmann-La Roche, 4.	Key Developments, Pfizer, Bristol-Myers Squibb, Inc., Boehringer Ingelheim GmbH, Sanofi, Daiichi Sankyo, AstraZeneca, Inc., Immunocore, Ltd, Biogen Inc., Merck and Co. Inc.

표 목록 (Tables)

List of Tables Table 1 Global Intratumoral Cancer Therapies Market Value, By Intratumoral Agent, 2025, 2029 & 2033 (US$ Million)

Table 2 Global Intratumoral Cancer Therapies Market Value, By Cancer Type, 2025, 2029 & 2033 (US$ Million)

Table 3 Global Intratumoral Cancer Therapies Market Value, By End User, 2025, 2029 & 2033 (US$ Million)

Table 4 Global Intratumoral Cancer Therapies Market Value, By Region, 2025, 2029 & 2033 (US$ Million)

Table 5 Global Intratumoral Cancer Therapies Market Value, By Intratumoral Agent, 2025, 2029 & 2033 (US$ Million)

Table 6 Global Intratumoral Cancer Therapies Market Value, By Intratumoral Agent, 2022-2033 (US$ Million)

Table 7 Global Intratumoral Cancer Therapies Market Value, By Cancer Type, 2025, 2029 & 2033 (US$ Million)

Table 8 Global Intratumoral Cancer Therapies Market Value, By Cancer Type, 2022-2033 (US$ Million)

Table 9 Global Intratumoral Cancer Therapies Market Value, By End User, 2025, 2029 & 2033 (US$ Million)

Table 10 Global Intratumoral Cancer Therapies Market Value, By End User, 2022-2033 (US$ Million)

Table 11 Global Intratumoral Cancer Therapies Market Value, By Region, 2025, 2029 & 2033 (US$ Million)

Table 12 Global Intratumoral Cancer Therapies Market Value, By Region, 2022-2033 (US$ Million)

Table 13 North America Intratumoral Cancer Therapies Market Value, By Intratumoral Agent, 2022-2033 (US$ Million)

Table 14 North America Intratumoral Cancer Therapies Market Value, By Cancer Type, 2022-2033 (US$ Million)

Table 15 North America Intratumoral Cancer Therapies Market Value, By End User, 2022-2033 (US$ Million)

Table 16 North America Intratumoral Cancer Therapies Market Value, By Country, 2022-2033 (US$ Million)

Table 17 Asia-Pacific Intratumoral Cancer Therapies Market Value, By Intratumoral Agent, 2022-2033 (US$ Million)

Table 18 Asia-Pacific Intratumoral Cancer Therapies Market Value, By Cancer Type, 2022-2033 (US$ Million)

Table 19 Asia-Pacific Intratumoral Cancer Therapies Market Value, By End User, 2022-2033 (US$ Million)

Table 20 Asia-Pacific Intratumoral Cancer Therapies Market Value, By Country, 2022-2033 (US$ Million)

Table 21 Europe Intratumoral Cancer Therapies Market Value, By Intratumoral Agent, 2022-2033 (US$ Million)

Table 22 Europe Intratumoral Cancer Therapies Market Value, By Cancer Type, 2022-2033 (US$ Million)

Table 23 Europe Intratumoral Cancer Therapies Market Value, By End User, 2022-2033 (US$ Million)

Table 24 Europe Intratumoral Cancer Therapies Market Value, By Country, 2022-2033 (US$ Million)

Table 25 South America Intratumoral Cancer Therapies Market Value, By Intratumoral Agent, 2022-2033 (US$ Million)

Table 26 South America Intratumoral Cancer Therapies Market Value, By Cancer Type, 2022-2033 (US$ Million)

Table 27 South America Intratumoral Cancer Therapies Market Value, By End User, 2022-2033 (US$ Million)

Table 28 South America Intratumoral Cancer Therapies Market Value, By Country, 2022-2033 (US$ Million)

Table 29 Middle East and Africa Intratumoral Cancer Therapies Market Value, By Intratumoral Agent, 2022-2033 (US$ Million)

Table 30 Middle East and Africa Intratumoral Cancer Therapies Market Value, By Cancer Type, 2022-2033 (US$ Million)

Table 31 Middle East and Africa Intratumoral Cancer Therapies Market Value, By End User, 2022-2033 (US$ Million)

Table 32 Middle East and Africa Intratumoral Cancer Therapies Market Value, By Country, 2022-2033 (US$ Million)

Table 33 DAIICHI SANKYO COMPANY, LIMITED: Overview

Table 34 DAIICHI SANKYO COMPANY, LIMITED: Product Portfolio

Table 35 DAIICHI SANKYO COMPANY, LIMITED: Key Developments

Table 36 Amgen Inc.: Overview

Table 37 Amgen Inc.: Product Portfolio

Table 38 Amgen Inc.: Key Developments

Table 39 Shanghai Sunway Biotech Co., Ltd.: Overview

Table 40 Shanghai Sunway Biotech Co., Ltd.: Product Portfolio

Table 41 Shanghai Sunway Biotech Co., Ltd.: Key Developments

Table 42 Others: Overview

Table 43 Others: Product Portfolio

Table 44 Others: Key Developments

그림 목록 (Figures)

List of Figures Figure 1 Global Intratumoral Cancer Therapies Market Value, 2022-2033 (US$ Million)

Figure 2 Global Intratumoral Cancer Therapies Market Share, By Intratumoral Agent, 2024 & 2033 (%)

Figure 3 Global Intratumoral Cancer Therapies Market Share, By Cancer Type, 2024 & 2033 (%)

Figure 4 Global Intratumoral Cancer Therapies Market Share, By End User, 2024 & 2033 (%)

Figure 5 Global Intratumoral Cancer Therapies Market Share, By Region, 2024 & 2033 (%)

Figure 6 Global Intratumoral Cancer Therapies Market Y-o-Y Growth, By Intratumoral Agent, 2023-2033 (%)

Figure 7 Stationary Intratumoral Cancer Therapies Market Value, 2022-2033 (US$ Million)

Figure 8 Mobile/Portable Intratumoral Cancer Therapies Market Value, 2022-2033 (US$ Million)

Figure 9 Manual Intratumoral Cancer Therapies Market Value, 2022-2033 (US$ Million)

Figure 10 Global Intratumoral Cancer Therapies Market Y-o-Y Growth, By Cancer Type, 2023-2033 (%)

Figure 11 Electric-powered Cancer Type in Global Intratumoral Cancer Therapies Market Value, 2022-2033 (US$ Million)

Figure 12 Battery-powered Cancer Type in Global Intratumoral Cancer Therapies Market Value, 2022-2033 (US$ Million)

Figure 13 Manual Cancer Type in Global Intratumoral Cancer Therapies Market Value, 2022-2033 (US$ Million)

Figure 14 Global Intratumoral Cancer Therapies Market Y-o-Y Growth, By End User, 2023-2033 (%)

Figure 15 Respiratory Care End User in Global Intratumoral Cancer Therapies Market Value, 2022-2033 (US$ Million)

Figure 16 Surgical and Wound Care End User in Global Intratumoral Cancer Therapies Market Value, 2022-2033 (US$ Million)

Figure 17 Obstetrics & Gynecology (Delivery Rooms) End User in Global Intratumoral Cancer Therapies Market Value, 2022-2033 (US$ Million)

Figure 18 Emergency Care End User in Global Intratumoral Cancer Therapies Market Value, 2022-2033 (US$ Million)

Figure 19 Others End User in Global Intratumoral Cancer Therapies Market Value, 2022-2033 (US$ Million)

Figure 20 Global Intratumoral Cancer Therapies Market Y-o-Y Growth, By Region, 2023-2033 (%)

Figure 21 North America Intratumoral Cancer Therapies Market Value, 2022-2033 (US$ Million)

Figure 22 North America Intratumoral Cancer Therapies Market Share, By Intratumoral Agent, 2024 & 2033 (%)

Figure 23 North America Intratumoral Cancer Therapies Market Share, By Cancer Type, 2024 & 2033 (%)

Figure 24 North America Intratumoral Cancer Therapies Market Share, By End User, 2024 & 2033 (%)

Figure 25 North America Intratumoral Cancer Therapies Market Share, By Country, 2024 & 2033 (%)

Figure 26 Asia-Pacific Intratumoral Cancer Therapies Market Value, 2022-2033 (US$ Million)

Figure 27 Asia-Pacific Intratumoral Cancer Therapies Market Share, By Intratumoral Agent, 2024 & 2033 (%)

Figure 28 Asia-Pacific Intratumoral Cancer Therapies Market Share, By Cancer Type, 2024 & 2033 (%)

Figure 29 Asia-Pacific Intratumoral Cancer Therapies Market Share, By End User, 2024 & 2033 (%)

Figure 30 Asia-Pacific Intratumoral Cancer Therapies Market Share, By Country, 2024 & 2033 (%)

Figure 31 Europe Intratumoral Cancer Therapies Market Value, 2022-2033 (US$ Million)

Figure 32 Europe Intratumoral Cancer Therapies Market Share, By Intratumoral Agent, 2024 & 2033 (%)

Figure 33 Europe Intratumoral Cancer Therapies Market Share, By Cancer Type, 2024 & 2033 (%)

Figure 34 Europe Intratumoral Cancer Therapies Market Share, By End User, 2024 & 2033 (%)

Figure 35 Europe Intratumoral Cancer Therapies Market Share, By Country, 2024 & 2033 (%)

Figure 36 South America Intratumoral Cancer Therapies Market Value, 2022-2033 (US$ Million)

Figure 37 South America Intratumoral Cancer Therapies Market Share, By Intratumoral Agent, 2024 & 2033 (%)

Figure 38 South America Intratumoral Cancer Therapies Market Share, By Cancer Type, 2024 & 2033 (%)

Figure 39 South America Intratumoral Cancer Therapies Market Share, By End User, 2024 & 2033 (%)

Figure 40 South America Intratumoral Cancer Therapies Market Share, By Country, 2024 & 2033 (%)

Figure 41 Middle East and Africa Intratumoral Cancer Therapies Market Value, 2022-2033 (US$ Million)

Figure 42 Middle East and Africa Intratumoral Cancer Therapies Market Share, By Intratumoral Agent, 2024 & 2033 (%)

Figure 43 Middle East and Africa Intratumoral Cancer Therapies Market Share, By Cancer Type, 2024 & 2033 (%)

Figure 44 Middle East and Africa Intratumoral Cancer Therapies Market Share, By End User, 2024 & 2033 (%)

Figure 45 DAIICHI SANKYO COMPANY, LIMITED: Financials

Figure 46 Amgen Inc.: Financials

Figure 47 Shanghai Sunway Biotech Co., Ltd.: Financials

Figure 48 Others: Financials

글로벌 종양내 항암 치료 시장 – 2023-2030

Global Intratumoral Cancer Therapies Market - 2023-2030